Stay Alert for Patients on Hep C Meds Reporting High or Low Blood Sugars

April 2020

Health Canada is warning about possible blood sugar changes in patients who take certain hep C meds.

The concern is with newer hepatitis meds called "direct-acting antivirals"...such as Epclusa, Maviret, and Zepatier.

There are reports of patients having low or high blood glucose levels or developing diabetes while taking these meds.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Storage & Disposal Highlight Med Disposal Options for Patients
Migraine Expect Fewer Rxs to Prevent Migraine in Kids
Practice Follow Best Practices for Billing Insulin Pens
Allergic Reactions Ask Questions to Help Clarify Penicillin Allergies in Kids
Respiratory & Allergy Don't Be Surprised to See Alternatives to Montelukast for Seasonal Allergies
Practice Keep an Eye Out for Patients With Vision Problems
Inventory Management Use Strategies to Minimize Pharmacy Shrink
Med Safety Reduce the Risk of Mishaps Related to Knowledge, Action, or Memory
Hepatitis C Stay Alert for Patients on Hep C Meds Reporting High or Low Blood Sugars